FORGOT YOUR PASSWORD?
MEMBERSHIP REGISTRATION
Mission & Vision

Bioterrorism

Education Resources

References & Links

Board Members

Current ISMR Activities

Recent ISMR Programs









Antimicrobial Drug Resistance (AMDR)

Print this section

Print entire program

          e. Influenza virus



e. Influenza virus

Influenza A viruses—including the 2 subtypes 2009 (H1N1) and A (H3N2)—and influenza B viruses are currently circulating worldwide. The pandemic H1N1 is becoming the predominant strain in both hemispheres with an increased activity in the Southeast Asia (Nicogossian et al. 2010). 

It is estimated that worldwide, influenza viruses are responsible for infecting 1 billion individuals annually, resulting in 300,000 to 500,000 deaths. The economic burden in the US alone is a staggering US $1 to 3 billion, annually attributed to related absenteeism, secondary respiratory bacterial infections, hospitalizations, and use of scarce and costly medical resources. 

Primary protective measures consist of a combination of vaccinations, environmental and physical hygiene practices, and, in appropriate settings, the use of antiviral drugs to either prevent or shorten the course of the infection. Recently, however, resistance to antiviral drugs was reported (Glickman et al. 2010; Memoli et al. 2010; Bright et al. 2006; Gooskens et al. 2009). 

In the United States, the CDC has issued interim recommendations and updates for the prevention of the development of resistance to antiviral medications (Centers for Disease Control and Prevention 2009; Centers for Disease Control and Prevention 2010). Recently, influenza has been implicated as a contributing factor in the development of AMDR and fatal MRSA pneumonia (Creel et al. 2009; Pedal and Nolte 2010)




Previous Section    Next Section   
Table of Contents

ACTIVITY OVERVIEW
INTRODUCTION
SECTION ONE: The global threat of AMDR
SECTION TWO: Understanding AMDR
    1. Etiology and Epidemiology
    2. Incidence and Prevalence of Microbial Resistance
    3. Major AMDR Pathogens
       a. Acinetobacter baumanii
       b. Clostridium difficile
       c. Escherichia coli
       d. HIV/AIDS and Sexually Transmitted Infection
       e. Influenza virus
       f. Malaria (Plasmodium)
       g. Methicillin-resistant Staphylococcus aureus (MRSA)
       h. Streptococcus pneumoniae
       i. Tuberculosis and MDR-TB
       j. Vancomycin-Resistant Enterococcus (VRE)
SECTION THREE: Control and Prevention of AMDR
    1. Implications of Microbial Resistance
    2. Infections and Chronic Diseases
    3. Policies and Best Practices
       a. Antimicrobial Drug Stewardship
       b. Surveillance
       c. Environmental Decontamination
       d. Infection Control
       e. Patient Education
    4. Antibiotic Development Pipeline
SECTION FOUR: Conclusions
REFERENCES
APPENDICES
GLOSSARY
Test Questions
Program Evaluation
Self Assessment


© 2018, International Society of Microbial Resistance    |    Terms of Use & Disclaimer